Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the <scp>GRIFFIN</scp> study-Reference-Cited by-同舟云学术

Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study

Published:2022-09-16 Issue:3 Volume:199 Page:355-365
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Sborov Douglas W.¹^ORCID,Baljevic Muhamed²,Reeves Brandi³,Laubach Jacob⁴^ORCID,Efebera Yvonne A.⁵,Rodriguez Cesar⁶,Costa Luciano J.⁷^ORCID,Chari Ajai⁸,Silbermann Rebecca⁹,Holstein Sarah A.¹⁰,Anderson Larry D.¹¹^ORCID,Kaufman Jonathan L.¹²^ORCID,Shah Nina¹³,Pei Huiling¹⁴,Patel Sharmila¹⁵,Cortoos Annelore¹⁵,Bartlett J. Blake¹⁶,Vermeulen Jessica¹⁷,Lin Thomas S.¹⁵,Voorhees Peter M.¹⁸^ORCID,Richardson Paul G.⁴^ORCID

Affiliation:

1. Huntsman Cancer Institute University of Utah School of Medicine Salt Lake City Utah USA

2. Division of Oncology & Hematology, Department of Internal Medicine Vanderbilt University Medical Center Nashville Tennessee USA

3. University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

4. Dana‐Farber Cancer Institute Boston Massachusetts USA

5. OhioHealth Columbus Ohio USA

6. Wake Forest University School of Medicine Winston‐Salem North Carolina USA

7. University of Alabama at Birmingham Birmingham Alabama USA

8. Tisch Cancer Institute, Mount Sinai School of Medicine New York New York USA

9. Knight Cancer Institute, Oregon Health & Science University Portland Oregon USA

10. Divison of Oncology & Hematology, Department of Internal Medicine University of Nebraska Medical Center Omaha Nebraska USA

11. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center Dallas Texas USA

12. Winship Cancer Institute, Emory University Atlanta Georgia USA

13. Department of Medicine University of California San Francisco San Francisco California USA

14. Janssen Research & Development, LLC Titusville New Jersey USA

15. Janssen Scientific Affairs, LLC Horsham Pennsylvania USA

16. Janssen Research & Development, LLC Raritan New Jersey USA

17. Janssen Research & Development, LLC Leiden The Netherlands

18. Levine Cancer Institute Atrium Health Charlotte North Carolina USA

Funder

Janssen Pharmaceuticals

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.18432

Reference24 articles.

1. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study

2. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

3. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

4. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis

5. Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ‘X’ marks the spot! Utilising factor Xa inhibitors to optimise thromboprophylaxis in multiple myeloma;British Journal of Haematology;2024-07-10

2. Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines;Annals of Hematology;2024-04-17

3. Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta‐analysis;American Journal of Hematology;2024-03-15

4. Cancer-associated thrombosis in hematologic malignancies;International Journal of Hematology;2024-01-25

5. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group;Thrombosis Research;2024-01